Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone

Scandinavian Journal of Work, Environment and Health

Volumn 30, Issue 4, 2004, Pages 306-312

  Åkesson, Bengt ^a   Carnerup, Martin A ^a   Jönsson, Bo A G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biological monitoring; Developmental toxicity; Skin uptake; Solvent

Indexed keywords

1 METHYL 2 PYRROLIDINONE; BIOLOGICAL MARKER; INDUSTRIAL CHEMICAL; WATER;

BIOMARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL TOXICOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN ABSORPTION; TOXICOKINETICS; URINALYSIS;

EID: 4444262009     PISSN: 03553140     EISSN: None     Source Type: Journal    
DOI: 10.5271/sjweh.799     Document Type: Article

References (23)

1. Åkesson B. Nordic expert group for criteria documentation of health risks from chemicals: 115. N-methyl-2-pyrrolidone (NMP). Stockholm: Arbetarskyddsverket; 1994. Arbete och Hälsa 40:1-24.
2. Becci PJ, Knickerbocker MJ, Raegan EL, Parent RA, Burnette LW. Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats. Fundam Appl Toxicol 1982;2:73-6.
3. Saillenfait AM, Gallisso F, Morel G. Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure. Food Chem Toxicol 2003;41:583-8.
4. Saillenfait AM, Gallissot F, Langonné I, Sabaté JP. Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. Food Chem Toxicol 2002;40:1705-12.
5. Solomon GM, Morse EP, Garbo MJ, Milton DK. Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. J Occup Environ Med 1996;38:705-13.
6. Malley LA, Kennedy GL, Elliott GS, Slone TW, Mellert W, Deckhardt K, et al. Chronic toxicity and oncogenicity of N-methylpyrrolidone (NMP) in rats and mice by dietary administration. Drug Chem Toxicol 2001;24:315-38.
7. Beaulieu HJ, Schmerber KR. M-Pyrol™ (NMP) use in the microelectronics industry. Appl Occup Environ Hyg 1991;6:874-80.
8. Langworth S, Anundi H, Friis L, Johanson G, Lind M-L, Söderman E, et al. Acute health effects common during graffiti removal. Int Arch Occup Environ Health 2001;74:213-8.
9. Åkesson B, Paulsson K. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. Occup Environ Med 1997;54:236-40.
10. International Program on Chemical Safety (IPCS). No 35 N-methyl-2-pyrrolidone. Geneva: World Health Organization; 2001.
11. Åkesson B, Jönsson BAG. Major metabolic pathway for N-methyl-2-pyrrolidone in humans. Drug Metab Dispos 1997;25:267-9.
12. Akrill P, Cocker J, Dixon S. Dermal exposure to aqueous solutions of N-methylpyrrolidone. Toxicol Lett 2002;134:265-9.
13. Anundi H, Langworth S, Johanson G, Lind M-L, Åkesson B, Friis L, et al. Air and biological monitoring of solvent exposure during graffiti removal. Int Arch Occup Environ Health 2000;73:561-9.
14. Carnerup MA, Åkesson B, Jönsson BAG. Determination of 5-hydroxy-N-methyl-2-pyrrolidone and 2-hydroxy-N-methylsuccinimide in human plasma and urine using liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B 2001;761:107-13.
15. Jönsson BAG, Åkesson B. Determination of N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide in human urine and plasma. J Chromatogr B 1997;704:151-8.
16. Åkesson B, Jönsson BAG. Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. Scand J Work Environ Health 2000;26:213-8.
17. Jönsson BAG, Åkesson B. Human experimental exposure to N-methyl-2-pyrrolidone (NMP): toxikokinetics of NMP, 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide (2-HMSI), and biological monitoring using 2-HMSI as a biomarker. Int Arch Environ Health 2003;76:267-74.
18. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J 1993;54:615-27.
19. Lustgarten JA, Wenk RE. Simple, rapid, kinetic method for serum creatinine measurement. Clin Chem 1972;18:1419-22.
20. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1995.
21. Jönsson BAG, Åkesson B. N-Methylsuccinimide in plasma and urine as a biomarker of exposure to N-methyl-2-pyrrolidone. Int Arch Occup Environ Health 2001;74:289-94.
22. Jönsson BAG, Åkesson B. Analysis of 5-Hydroxy-N-Methyl-2-Pyrrolidone and 2-Hydroxy-N-Methylsuccinimide in Plasma. Chromatographia 1997;46:141-4.
23. Jönsson BAG, Åkesson B. Determination of 5-hydroxy-N-methylpyrrolidone and 2-hydroxy-N-methylsuccinimide in human urine. J Chromatogr B 1997;694:351-7.